{"nctId":"NCT01636206","briefTitle":"Safety Study of Lifitegrast to Treat Dry Eye","startDateStruct":{"date":"2012-10-16","type":"ACTUAL"},"conditions":["Dry Eye Disease"],"count":332,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Lifitegrast","type":"EXPERIMENTAL","interventionNames":["Drug: Lifitegrast"]}],"interventions":[{"name":"Lifitegrast","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Willing and able to read, sign and date the informed consent and HIPAA documents\n* Willing and able to comply with all study procedures\n* Be at least 18 years of age\n* Patient-reported history of dry eye in both eyes\n* A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period\n\nExclusion Criteria:\n\n* Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy\n* Unwilling to avoid wearing contact lenses for 24h prior to Visit 1 and for some duration during the study\n* Any blood donation or significant loss of blood within 56 days of Visit 1\n* Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.\n* Use of any prohibited medications during the appropriate pre-study washout period and at any time during the study unless otherwise specified\n* Any significant illness that could interfere with study parameters\n* History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 12 months prior to Visit 1; or any scheduled ocular surgical procedure during the study period.\n* Known history of alcohol and/or drug abuse\n* Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Ocular and Nonocular Treatment Emergent Adverse Events (TEAEs) for 1 Year","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":111},"commonTop":["Instillation site irritation","Dysgeusia","Visual acuity reduced","Instillation site reaction","Dry eye"]}}}